Search Within

Anthony R Mato

Formats
  1. Meeting Abstract (135)
  2. Journal Article (63)
  3. Review (16)
  4. Research Letter (10)
  5. Editorial (7)
  6. Guidelines (3)
  7. Book Section (1)
  8. Miscellaneous (1)
Groups
  1. Adult Leukemia (236)
  2. Center for Hematologic Malignancies (236)
  3. Department of Medicine (236)
  4. Hematologic Malignancies, Division of (236)
  5. Hematology-Oncology Fellows (101)
  6. Lymphoma (47)

More Groups

People
  1. Lindsey Roeker (94)
  2. Andrew Zelenetz (33)
  3. Meghan Thompson (30)
  4. Omar Abdel-Wahab (19)
  5. Maria Palomba (18)
  6. Colleen Dorsey (14)

More People

Years
  1. 2025 (4)
  2. 2024 (2)
  3. 2023 (22)
  4. 2022 (49)
  5. 2021 (39)
  6. 2020 (52)

More Years

Publications
  1. Blood (82)
  2. Journal of Clinical Oncology (18)
  3. Clinical Lymphoma, Myeloma and Leukemia (16)
  4. Leukemia and Lymphoma (16)
  5. British Journal of Haematology (15)
  6. Blood Advances (10)

More Publications

Publishers
  1. American Society of Hematology (94)
  2. American Society of Clinical Oncology (19)
  3. Elsevier Inc. (18)
  4. Taylor & Francis Group (18)
  5. John Wiley & Sons (16)
  6. American Association for Cancer Research (10)

More Publishers

Results (236)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Combinations or sequences of targeted agents in CLL: Is the whole greater than the sum of its parts (Aristotle, 360 BC)?
    Editorial

    Yazdy, M. S.; Mato, A. R.; Cheson, B. D.
    Blood (2019)

    Fulltext@MSK | Save
  • Racial, age, and sex disparities in chronic lymphocytic leukemia (CLL) patients treated with novel therapies
    Meeting Abstract

    Thompson, M.; Nabhan, C.; Cheson, B. D.; Allan, J. N.; Barr, P. M.; Skarbnik, A. P.; Jacobs, R.; Ujjani, C. S.; Furman, R. R.; Schuster, S. J.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Physicians' documented performance of shared decision-making with chronic lymphocytic leukemia patients
    Meeting Abstract

    Mato, A. R.; Davids, M. S.; Carter, J. D.; Greene, L.; Sapir, T.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Outcomes of patients with MYC-expressing aggressive B cell non-Hodgkin lymphomas who fail two or more lines of therapy
    Meeting Abstract

    Landsburg, D. J.; Nasta, S.; Svoboda, J.; Mato, A. R.; Schuster, S. J.; Sargent, R. L.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Tolerability and response of the novel SYK/JAK inhibitor cerdulatinib in a phase 2a study in relapsed/refractory peripheral T cell lymphoma (PTCL)
    Meeting Abstract

    Horwitz, S. M.; Hamlin, P. A.; Feldman, T.; Hess, B. T.; Mato, A. R.; Munoz, J.; Patel, M. R.; Ye, J. C.; Steele, A.; Pandey, A.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Mutations in the RNA splicing factor SF3B1 promote transformation through MYC stabilization
    Meeting Abstract

    Yoshimi, A.; Liu, Z.; Wang, J.; Cho, H.; Lee, S. C.; Ki, M.; Bitner, L. E.; Chu, T.; Mato, A. R.; Ruvolo, P. P.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Front-line ibrutinib treatment is associated with longer time to next treatment, net total cost reduction, and lower healthcare resource utilization compared to chemoimmunotherapy in patients with chronic lymphocytic leukemia
    Meeting Abstract

    Wang, S.; Emond, B.; Romdhani, H.; Lefebvre, P.; Sundaram, M.; Mato, A. R.
    Blood (2018)

    Fulltext@MSK | Save
  • Chronic lymphocytic leukemia (CLL) transformed into Hodgkin lymphoma (HL): Clinical characteristics and outcomes from a large multi-center collaboration
    Meeting Abstract

    Stephens, D. M.; Boucher, K.; Kander, E.; Parikh, S. A.; Parry, E.; Shadman, M.; Pagel, J. M.; Cooperrider, J.; Rhodes, J.; Mato, A. R.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Chronic lymphocytic leukemia treatment patterns, dosing, and sequencing in the era of novel targeted therapies: Interim analysis results from the prospective informCLL (TM) real-world registry
    Meeting Abstract

    Sharman, J.; Barrientos, J. C.; Brander, D. M.; Pagel, J. M.; Gutierrez, M.; Kadish, K.; Tomlinson, B.; Ghosh, N.; Giafis, N.; Ipe, D.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Phase I/II study of umbralisib (TGR-1202) in combination with ublituximab (TG-1101) and pembrolizumab in patients with relapsed/refractory CLL and Richter's transformation
    Meeting Abstract

    Mato, A. R.; Svoboda, J.; Prak, E. T. L.; Schuster, S. J.; Tsao, P.; Dorsey, C.; Becker, P. S.; Brander, D. M.; Nasta, S. D.; Landsburg, D. J.; more...
    Blood (2018)

    Fulltext@MSK | Save